What is it about?
Depending on whether you wish to prove that a treatment has an effect, what its average effect will be in future or what its specific effect will be for a given patient, different approaches to analysing n-of-1 trials are required. This paper explains why and how to carry out the analyses.
Featured Image
Why is it important?
The current literature to n-of-1 trials is confusing and contradictory. This is because different authors have implicitly considered different purpose. By making purpose explicit to the process of analysing n-of-1 trials we have cleared up the confusion.
Perspectives
I have been involved with within-patient studies ever since I joined the pharmaceutical industry in 1987 and I wrote a book on the subject in 1993 (2nd edition 2002). Taking the work even further by considering repeated treatment within patients is a logical extension.
Professor Stephen J Senn
Consultant Statistician
Read the Original
This page is a summary of: Understanding Variation in Sets of N-of-1 Trials, PLoS ONE, December 2016, PLOS,
DOI: 10.1371/journal.pone.0167167.
You can read the full text:
Resources
Contributors
The following have contributed to this page
